Hutch News

New Science Spotlight Articles

Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
12 NEW March 20, 2023
Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow

Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow

Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald
Hutch News - October 06, 2022
Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy

Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy

Cancer biologist contributed basic and translational insights that made the cancer-preventive HPV vaccine possible
Hutch News - March 22, 2022
Seattle team pivotal to FDA OK on drug for rare skin cancer

Seattle team pivotal to FDA OK on drug for rare skin cancer

UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
News Releases - December 20, 2018
Molecular mechanisms of late cancer relapse

Molecular mechanisms of late cancer relapse

from the Chapuis lab, Clinical Research Division
Science Spotlight - October 15, 2018
Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

A Nature Communications report explains why some Merkel cell carcinoma patients treated with immunotherapy see their cancers shrink at first but then come back.
News Releases - September 24, 2018
Triple therapy for rare skin cancer shows promise in small, early-stage trial

Triple therapy for rare skin cancer shows promise in small, early-stage trial

Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Hutch News - May 31, 2017
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Hutch News - April 03, 2017